By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted May 9, 2024APYX MEDICAL CORPORATION ANNOUNCES BOARD LEADERSHIP TRANSITION READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted April 25, 2024APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2024 FINANCIAL RESULTS ON MAY 9, 2024 READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted April 11, 2024APYX MEDICAL CORPORATION SHOWCASES NEW DATA AND TREATMENT INSIGHTS AT THE RENUVION USERS’ SUMMIT READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted March 21, 2024APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2024 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted March 4, 2024APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS ON MARCH 21, 2024 READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted February 21, 2024APYX MEDICAL CORPORATION ANNOUNCES RENUVION TO BE FEATURED IN EDUCATIONAL SESSIONS AT THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) SCIENTIFIC MEETING READ MORE
By apyxmedical In 2024 Shareholder News, J-Plasma, RenuvionPosted January 22, 2024APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED CLINICAL PUBLICATION EVALUATING THE SAFETY OF RENUVION FOLLOWING LIPOSUCTION IN MULTIPLE AREAS OF THE BODY READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted January 8, 2024APYX MEDICAL CORPORATION REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2023 REVENUE RESULTS READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted November 28, 2023APYX MEDICAL CORPORATION APPOINTS MATTHEW HILL AS CHIEF FINANCIAL OFFICER READ MORE
By Nick Johnson (Apyx) In 2023 Shareholder News, J-Plasma, RenuvionPosted November 9, 2023APYX MEDICAL CORPORATION ANNOUNCES NEW DEBT FACILITY WITH PERCEPTIVE ADVISORS READ MORE
